CEP
BMRN icon

Chicago Equity Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Chicago Equity Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,380
Closed -$204K – 865
2019
Q2 		$204K Hold
2,380
– – 0.01% 857
2019
Q1 		$211K Buy
+2,380
New +$221K 0.01% 813

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Chicago Equity Partners's BMRN Position: Q3 2019 in Review

Chicago Equity Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2019, closing a stake of 2,380 shares — an estimated $204K sold.

Chicago Equity Partners first reported a position in BMRN in Q1 2019 and held it in 2 quarters. The position peaked at $211K in Q1 2019. 436 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

  • Chicago Equity Partners reported no remaining BioMarin Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Chicago Equity Partners sold 2,380 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $204K.
  • Chicago Equity Partners first reported a position in BioMarin Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Chicago Equity Partners's BioMarin Pharmaceuticals position peaked at $211K in Q1 2019.
  • 436 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on Chicago Equity Partners's 13F filing for Q3 2019, filed 30 Oct 2019.